Intra-arterial bevacizumab with blood brain barrier disruption in a glioblastoma xenograft model
Antibodies, Monoclonal, Humanized
In this study we showed a significant survival benefit of repeated IP BV and single IA BV with or without BBBD treated mice compared to single IP BV treated and control mice in a U87 xenograft model.
Additional Document Info
has global citation frequency